



Amended Claims:

1 (Currently Amended). A compound of formula (I),




or a pharmaceutically suitable salt or prodrug thereof, wherein  
A is a member selected from the group consisting of



B and C are each independently a member selected from the group consisting of aryl, and heterocycle;

R<sub>1</sub> is a member selected from the group consisting of alkyl, alkoxy, alkylSO<sub>2</sub>, trifluoroalkylSO<sub>2</sub>, trifluoroalkylNH-, alkylSO<sub>2</sub>NH-, carboxy, cyano, HONHcarbonyl, R<sub>a</sub>ONHcarbonyl, nitro, R<sub>a</sub>OC(O)-, HO<sub>3</sub>S-, H<sub>2</sub>NO<sub>2</sub>S-, R<sub>a</sub>NHO<sub>2</sub>S-, (HO)<sub>2</sub>(O)P-, (HO)<sub>2</sub>(O)PCH<sub>2</sub>-, (HO)<sub>2</sub>(O)PCHF-, (HO)<sub>2</sub>(O)PCF<sub>2</sub>- and heterocycle, wherein said heterocycle is a member selected from the group consisting of:



R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are each independently absent or are independently a member selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, aryl, arylcarbonyl, arylalkyl, carboxy, carboxyalkyl, cyano, cycloalkyl, cycloalkylalkyl, halo, haloalkyl, heterocycle, heterocyclecarbonyl, heterocyclealkyl, hydroxy, hydroxyalkyl, nitro, trihaloalkyl, R<sub>a</sub>R<sub>b</sub>N, R<sub>a</sub>R<sub>b</sub>Nalkyl, R<sub>a</sub>R<sub>b</sub>Ncarbonyl, R<sub>a</sub>R<sub>b</sub>Ncarbonylalkyl, R<sub>a</sub>R<sub>b</sub>NNsulfonyl, R<sub>a</sub>R<sub>b</sub>NNsulfonylalkyl, wherein R<sub>a</sub> and R<sub>b</sub> are each independently a member selected from the group consisting of hydrogen, alkyl, alkoxycarbonyl, alkylcarbonyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, and heterocyclealkyl;



L is  $-G-X_1-J-X_2-K-$  or a bond;

G, J and K are independently a member selected from the group consisting of a bond, alkyl, alkenyl, aryl and cycloalkyl, wherein said alkyl, alkenyl, aryl and cycloalkyl may be optionally substituted with a group consisting of alkoxy, alkyl, halogen, hydroxy, hydroxyalkyl, carboxy and R<sub>d</sub>R<sub>e</sub>N-, wherein R<sub>d</sub> and R<sub>e</sub> are each independently a member selected from the group consisting of hydrogen, alkyl, alkoxycarbonyl, alkylcarbonyl and arylalkyl;

X<sub>1</sub> and X<sub>2</sub> are each independently a member selected from the group consisting of a bond,  $-O-$ ,  $-N(R_c)-$ ,  $-N(R_c)C(O)-$ ,  $-C(O)N(R_c)-$ ,  $-N(R_c)S(O)_2-$ ,  $-S(O)_2N(R_c)-$ , and  $-C(O)$ , wherein R<sub>c</sub> is a member selected from the group consisting of hydrogen, alkyl and arylalkyl, provided that both X<sub>1</sub> and X<sub>2</sub> are not a bond; and


provided that if J is absent, then at least one of X<sub>1</sub> and X<sub>2</sub> must be absent.

2 (Currently Amended). A compound of formula (II),



or a pharmaceutically suitable salt or prodrug thereof, wherein

$R_1$  is a member selected from the group consisting of alkyl, alkoxy, alkylSO<sub>2</sub>, trifluoroalkylSO<sub>2</sub>, trifluoroalkylNH-, alkylSO<sub>2</sub>NH-, carboxy, cyano, HONHcarbonyl,  $R_a$ ONHcarbonyl, nitro,  $R_a$ OC(O)-, HO<sub>3</sub>S-, H<sub>2</sub>NO<sub>2</sub>S-,  $R_a$ NHO<sub>2</sub>S-, (HO)<sub>2</sub>(O)P-, (HO)<sub>2</sub>(O)PCH<sub>2</sub>-, (HO)<sub>2</sub>(O)PCHF-, (HO)<sub>2</sub>(O)PCF<sub>2</sub>- and heterocycle, wherein said heterocycle is a member selected from the group consisting of:



**R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub>** are each independently absent or are independently a member selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, aryl, arylcarbonyl, arylalkyl, carboxy, carboxyalkyl, cyano, cycloalkyl, cycloalkylalkyl, halo, haloalkyl, heterocycle, heterocyclecarbonyl, heterocyclealkyl, hydroxy, hydroxyalkyl, nitro, trihaloalkyl, R<sub>a</sub>R<sub>b</sub>N, R<sub>a</sub>R<sub>b</sub>Nalkyl, R<sub>a</sub>R<sub>b</sub>Ncarbonyl, , R<sub>a</sub>R<sub>b</sub>Ncarbonylalkyl, R<sub>a</sub>R<sub>b</sub>NNsulfonyl, R<sub>a</sub>R<sub>b</sub>NNsulfonylalkyl, wherein R<sub>a</sub> and R<sub>b</sub> are each independently a member selected from the group consisting of hydrogen, alkyl, alkoxycarbonyl, alkylcarbonyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, and heterocyclealkyl;

**L** is  $-G-X_1-J-X_2-K-$  **or a bond**;

**G, J and K** are independently a member selected from the group consisting of a bond, alkyl, alkenyl, aryl and cycloalkyl, wherein said alkyl, alkenyl, aryl and cycloalkyl may be optionally substituted with a group consisting of alkoxy, alkyl, halogen, hydroxy, hydroxyalkyl, carboxy and R<sub>d</sub>R<sub>e</sub>N-, wherein R<sub>d</sub> and R<sub>e</sub> are each independently a member selected from the group consisting of hydrogen, alkyl, alkoxycarbonyl, alkylcarbonyl and arylalkyl;

**X<sub>1</sub> and X<sub>2</sub>** are each independently a member selected from the group consisting of a bond,  $-O-$ ,  $-N(R_c)-$ ,  $-N(R_c)C(O)-$ ,  $-C(O)N(R_c)-$ ,  $-N(R_c)S(O)_2-$ ,  $-S(O)_2N(R_c)-$ , and  $-C(O)-$ , wherein R<sub>c</sub> is a member selected from the group consisting of hydrogen, alkyl and arylalkyl, **provided that both X<sub>1</sub> and X<sub>2</sub> are not a bond**; and

provided that if J is absent, then at least one of X<sub>1</sub> and X<sub>2</sub> must be absent.

**3 (Original).** The compound according to claim 2, wherein

G is a member selected from the group consisting of alkyl, alkenyl and cycloalkyl.

**4 (Original).** The compound according to claim 2, wherein

G is a member selected from the group consisting of alkyl, alkenyl and cycloalkyl; and

X<sub>1</sub>, J and K are a bond.

5 (Original). The compound according to claim 2, wherein  
G is a member selected from the group consisting of alkyl, alkenyl and cycloalkyl; and  
X<sub>1</sub>, J and K are a bond; and  
R<sub>1</sub> is CO<sub>2</sub>H.

6 (Original). The compound according to claim 5, a member selected from the group consisting of

5-((1E)-3-(3-hydroxy-2-  
(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;  
5-((3-(3-hydroxy-2-  
(methoxycarbonyl)phenoxy)butyl)phenyl)isoxazole-3-carboxylic acid;  
5-((2-(3-hydroxy-2-  
(methoxycarbonyl)phenoxy)ethyl)amino)phenyl)isoxazole-3-carboxylic acid;  
5-((3-(3-hydroxy-2-  
(methoxycarbonyl)phenoxy)propyl)phenyl)isoxazole-3-carboxylic acid;  
5-(2-fluoro-5-((1E)-3-(3-hydroxy-2-  
(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;  
5-((1S,2S)-2-((3-hydroxy-2-  
nitrophenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;  
5-((1S,2S)-2-((3-hydroxy-2-  
(methoxycarbonyl)phenoxy)methyl)cyclopropyl)phenyl)isoxazole-3-carboxylic acid;  
5-((3-(3-hydroxy-2-  
(methoxycarbonyl)phenoxy)butyl)-4-methoxyphenyl)isoxazole-3-carboxylic acid;  
5-(4-fluoro-3-(3-(3-hydroxy-2-  
(methoxycarbonyl)phenoxy)butyl)phenyl)isoxazole-3-carboxylic acid;  
5-((3-(3-hydroxy-2-  
(methoxycarbonyl)phenoxy)pentyl)phenyl)isoxazole-3-carboxylic acid;  
5-((1E)-3-(3-hydroxy-2-  
propionylphenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;  
5-((1E)-4-hydroxy-3-(3-hydroxy-2-  
(methoxycarbonyl)phenoxy)but-1-enyl)phenyl)isoxazole-3-carboxylic acid;

5-(1-(2-(3-hydroxy-2-(methoxycarbonyl)phenoxy)ethyl)-1H-indol-6-yl)isoxazole-3-carboxylic acid;  
5-(3-((1E)-3-(2-(acetylamino)-3-hydroxyphenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;  
5-(3-((1E)-3-(2-((benzylamino)carbonyl)-3-hydroxyphenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;  
5-(3-((1E)-3-(3-hydroxy-2-(methoxycarbonyl)-4-nitrophenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;  
4-amino-5-(3-((1E)-3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid;  
5-(3-((1E)-3-((3',5-dihydroxy-4-(methoxycarbonyl)-1,1'-biphenyl-3-yl)oxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid; and  
5-(3-((1E)-3-(3-hydroxy-2-(methoxycarbonyl)phenoxy)prop-1-enyl)phenyl)-4-(hydroxymethyl)isoxazole-3-carboxylic acid.

7 (Original). The compound according to claim 2, wherein  
 $X_1$  is a member selected from the group consisting of  $-\text{NH-}$  and  $-\text{NHC(O)-}$ .

8 (Original). The compound according to claim 2, wherein  
 $X_1$  is a member selected from the group consisting of  $-\text{NH-}$  and  $-\text{NHC(O)-}$ ; and  
 $G$  and  $K$  are a bond.

9 (Original). The compound according to claim 2, wherein  
 $X_1$  is a member selected from the group consisting of  $-\text{NH-}$  and  $-\text{NHC(O)-}$ ;  
 $G$  and  $K$  are a bond; and  
 $R_1$  is  $\text{CO}_2\text{H}$ .

10 (Original). The compound according to claim 9, a member selected from the group consisting of

5-(3-(((1-acetyl)amino)phenyl)isoxazole-3-carboxylic acid;  
5-(3-((2-(3-hydroxy-2-((methylamino)carbonyl)phenoxy)ethyl)amino)phenyl)isoxazole-3-carboxylic acid; and  
5-(3-((1E)-3-(3-hydroxy-2-((methylamino)carbonyl)phenoxy)prop-1-enyl)phenyl)isoxazole-3-carboxylic acid.

11 (Canceled). The compound according to claim 2 wherein  
 $L$  is a bond.

12 (Original). The compound according to claim 2 wherein

L is a bond; and

R<sub>1</sub> is CO<sub>2</sub>H.

13 (Original). The compound according to claim 12 that is

5-{3'-(3-(carboxy)isoxazol-5-yl)-1,1'-biphenyl-3-yl}isoxazole-3-carboxylic acid.

14 (Original). A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically suitable carrier.

15 (Canceled).

16 (Canceled).

17 (Canceled).

18 (Canceled).

19 (Canceled).